{"name":"Merus B.V.","slug":"merus-b-v","ticker":"","exchange":"","domain":"","description":"Merus B.V. is a clinical-stage biotechnology company focused on the discovery and development of innovative bispecific antibodies for the treatment of cancer. The company's pipeline includes several candidates in various stages of clinical development, with a focus on leveraging its proprietary Biclonics technology to enhance therapeutic efficacy.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":36133000,"revenueGrowth":-17.8,"grossMargin":0,"rdSpend":225368000,"netIncome":-215326000,"cash":293294000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2025-12-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9kXzJwWG9MTkJ0NjVaUnNxMVFySTdUQVgzY3pTU3FSTUtaT1JWU0cyN3VFTHRWT3c3WGs4RUdIaWFJZFlKUnpZdzg3ZFVyX3FkbmxON3BXRy1tekVsYnRpV0V1bkd6eWVEWUJmWlhZNFJiWlNtQi1YVVVR?oc=5","date":"2020-08-19","type":"pipeline","source":"marketscreener.com","summary":"Merus N.V.: Shareholders Board Members Managers and Company Profile | NL0011606264 - marketscreener.com","headline":"Merus N.V.: Shareholders Board Members Managers and Company Profile | NL0011606264","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZl93NVpHblUtUm9TNk5sd1Nod2huWkp1RXhVeF94TkhXOHVvTGlubW4xYjRTMzE3cjhXOHlCSXRwX0RKZGMxRU5YYndxUGtkdkJWMlJ1d0RlcTVIV3pGbzhabzdJZUlFUXBOczMwR2hPczJhYmRHWkYyeGhYUHpObFNsMDZSZU4wUVE2V2tKYkpVZUlla0EwVElFTQ?oc=5","date":"2014-04-03","type":"pipeline","source":"Contract Pharma","summary":"Alvotech and Finesse Enter Bio-Manufacturing Pact - Contract Pharma","headline":"Alvotech and Finesse Enter Bio-Manufacturing Pact","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":36133000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":36133000,"period":"2024-12-31"},{"value":43947000,"period":"2023-12-31"},{"value":41586000,"period":"2022-12-31"},{"value":49107000,"period":"2021-12-31"},{"value":29943000,"period":"2020-12-31"},{"value":31133000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":225368000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-215326000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":293294000,"cashHistory":[],"totalAssets":782693000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}